The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer

[1] Kim SJ(2013)Safety, compliance, and predictive parameters for dosage modification in adjuvant S-1 chemotherapy for gastric cancer Cancer Sci 104 116-23

[2] Kim YJ(2012)Adjuvant therapy for gastric cancer: revisiting the past to clarify the future J Clin Oncol 30 2297-9

[3] Kim JH(2006)Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 11-20

[4] Park Do J(2007)Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine N Engl J Med 357 1810-20

[5] Kim HH(2012)Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial Lancet (London, England) 379 315-21

[6] Lee JS(2001)Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction N Engl J Med 345 725-30

[7] Brooks GA(1998)Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715-20

[8] Enzinger PC(2011)Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies OncoTargets and therapy. 4 193-201

[9] Fuchs CS(2013)Adjuvant chemotherapy for elderly patients with gastric cancer after D2 gastrectomy PloS one 8 e53149-9

[10] Cunningham D(2010)7th edition of the AJCC cancer staging manual: stomach Ann Surg Oncol 17 3077-40

[1] Kim SJ(2013)Safety, compliance, and predictive parameters for dosage modification in adjuvant S-1 chemotherapy for gastric cancer Cancer Sci 104 116-23

[2] Kim YJ(2012)Adjuvant therapy for gastric cancer: revisiting the past to clarify the future J Clin Oncol 30 2297-9

[3] Kim JH(2006)Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 11-20

[4] Park Do J(2007)Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine N Engl J Med 357 1810-20

[5] Kim HH(2012)Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial Lancet (London, England) 379 315-21

[6] Lee JS(2001)Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction N Engl J Med 345 725-30

[7] Brooks GA(1998)Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715-20

[8] Enzinger PC(2011)Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies OncoTargets and therapy. 4 193-201

[9] Fuchs CS(2013)Adjuvant chemotherapy for elderly patients with gastric cancer after D2 gastrectomy PloS one 8 e53149-9

[10] Cunningham D(2010)7th edition of the AJCC cancer staging manual: stomach Ann Surg Oncol 17 3077-40